Pathway analysis revealed metabolic enrichment alongside regulatory insights from HOXA10 and CNTN3, highlighting the integrated contribution of metabolic and transcriptional regulation to immunotherapy outcomes in HCC and suggesting therapeutic targets for combination strategies where metabolic modulators could enhance immunotherapy efficacy. Here, HOXA10 is linked to hepatocellular carcinoma.